Novo Nordisk (NVO) analyst forecast and price target
Analyst forecast
Consensus of 5 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Goldman Sachs | Downgraded | Buy → Neutral | $41.00 from $63.00 | Mar 2, 2026 |
| JP Morgan | Downgraded | Overweight → Neutral | — | Feb 24, 2026 |
| CICC | Initiated Coverage | Outperform | $73.50 | Jan 9, 2026 |
| Argus Research | Downgraded | Buy → Hold | — | Dec 8, 2025 |
| Goldman Sachs | Maintained | Buy | $54.00 from $60.00 | Nov 28, 2025 |
| BMO Capital | Maintained | Market Perform | $46.00 from $50.00 | Nov 25, 2025 |
| HSBC | Downgraded | Buy → Hold | — | Nov 24, 2025 |
| Jefferies | Initiated Coverage | Underperform | — | Oct 27, 2025 |
| BMO Capital | Maintained | Market Perform | $55.00 from $50.00 | Oct 14, 2025 |
| HSBC | Upgraded | Hold → Buy | $70.00 | Oct 2, 2025 |
| Morgan Stanley | Downgraded | Equal-Weight → Underweight | $47.00 from $59.00 | Sep 29, 2025 |
| Berenberg | Upgraded | Hold → Buy | — | Sep 17, 2025 |
| TD Cowen | Maintained | Buy | $70.00 from $105.00 | Aug 19, 2025 |
| UBS | Downgraded | Buy → Neutral | — | Aug 5, 2025 |
| HSBC | Downgraded | Buy → Hold | — | Jul 31, 2025 |
| Barclays | Downgraded | Overweight → Equal-Weight | — | Jul 30, 2025 |
| BMO Capital | Downgraded | Outperform → Market Perform | $64.00 from $105.00 | Apr 17, 2025 |
| UBS | Upgraded | Sell → Buy | — | Jan 8, 2025 |
| BMO Capital | Maintained | Outperform | $105.00 from $156.00 | Dec 23, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | $160.00 | Nov 6, 2024 |
Frequently asked questions
Is NVO a buy, sell, or hold?
Analysts covering Novo Nordisk currently average a Hold rating: 1 buy, 3 hold and 1 sell, from 5 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on NVO?
On Mar 2, 2026, Goldman Sachs downgraded Novo Nordisk to Neutral with a price target of $41.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.